Class Actions · Mass Torts · Securities FraudCall (918) 238-6445

Attorney advertisingBriefConsumer & Data Privacy

States seek final approval of $29.6M Glenmark generic-drug price-fixing settlement

Responsible attorney: Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. intake@snalawyers.com

A coalition of 48 states and territories asked a Connecticut federal judge on October 30, 2026 to grant final approval to a $29.6 million settlement with Glenmark Pharmaceuticals resolving allegations that it conspired with competitors to inflate prices and allocate markets for generic prescription drugs. The settlement, which received preliminary approval in August 2026, would pay restitution to the states and eligible consumers and requires Glenmark to cooperate in the states' ongoing case against dozens of other corporate and individual defendants. The underlying multistate antitrust litigation, led by the Connecticut Attorney General's office, has been pending since 2016 and is nearing its first trial.

Why it matters. Final approval would add another sizable recovery to the long-running generic-drug price-fixing litigation, offering a benchmark for consumers and payers evaluating claims against remaining defendants.

Ask the intake assistant about this

Sources

  1. Law360 secondary

Briefs summarize public developments. Unless stated otherwise, the firm is not counsel in the matters described, and allegations are not findings.

General information, not legal advice. Reading this article or using the intake assistant does not create an attorney-client relationship.

If something happened to more people than you, tell us.

Many class actions begin with one person who noticed a pattern. Reviewing your information costs nothing and creates no obligation.